FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8141人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839746, encodeId=fdc51839e469b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, objectType=article, longId=183460, objectId=fde3183460df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde3183460df, replyNumber=0, likeNumber=69, createdTime=2020-06-30, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde3183460df, moduleTitle=FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde3183460df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839797, encodeId=071d1839e977e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=**胆管癌靶向治疗药物获得美国FDA批准！, objectType=article, longId=192585, objectId=36c019258504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c019258504, replyNumber=0, likeNumber=81, createdTime=2021-03-15, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c019258504, moduleTitle=**胆管癌靶向治疗药物获得美国FDA批准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c019258504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839832, encodeId=eaba18398323c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=慢性皮肤病及呼吸道疾病患者的福音：FDA批准Dupixent（dupilumab）300mg预填充笔, objectType=article, longId=196203, objectId=838b196203df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=838b196203df, replyNumber=0, likeNumber=62, createdTime=2021-01-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=838b196203df, moduleTitle=慢性皮肤病及呼吸道疾病患者的福音：FDA批准Dupixent（dupilumab）300mg预填充笔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=838b196203df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839824, encodeId=40eb18398241e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准默沙东的抗生素组合Recarbrio，治疗细菌性肺炎, objectType=article, longId=195446, objectId=495f195446c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=495f195446c7, replyNumber=0, likeNumber=53, createdTime=2021-02-25, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=495f195446c7, moduleTitle=FDA批准默沙东的抗生素组合Recarbrio，治疗细菌性肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=495f195446c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839866, encodeId=15721839866de, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准XARACOLL（盐酸布比卡因）植入物，用于缓解术后疼痛, objectType=article, longId=200108, objectId=4842200108e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4842200108e6, replyNumber=0, likeNumber=83, createdTime=2021-01-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4842200108e6, moduleTitle=FDA批准XARACOLL（盐酸布比卡因）植入物，用于缓解术后疼痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4842200108e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839831, encodeId=be2a1839831e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=糖尿病性胃轻瘫：FDA批准甲氧氯普胺鼻喷剂Gimoti上市, objectType=article, longId=196201, objectId=0f2619620131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f2619620131, replyNumber=0, likeNumber=81, createdTime=2021-04-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f2619620131, moduleTitle=糖尿病性胃轻瘫：FDA批准甲氧氯普胺鼻喷剂Gimoti上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f2619620131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839822, encodeId=531c183982263, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, objectType=article, longId=195114, objectId=ab2419511413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab2419511413, replyNumber=0, likeNumber=75, createdTime=2020-07-16, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab2419511413, moduleTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab2419511413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839858, encodeId=5d9e1839858ec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, objectType=article, longId=198563, objectId=ec5d198563ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5d198563ab, replyNumber=0, likeNumber=78, createdTime=2021-03-06, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5d198563ab, moduleTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5d198563ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839724, encodeId=24161839e2411, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=20年首次突破！FDA批准卡格列净治疗“糖尿病肾病”适应症！, objectType=article, longId=180366, objectId=2ba31803668c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ba31803668c, replyNumber=0, likeNumber=80, createdTime=2020-07-15, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ba31803668c, moduleTitle=20年首次突破！FDA批准卡格列净治疗“糖尿病肾病”适应症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ba31803668c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839726, encodeId=4b4d1839e26f3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Galderma的新型类维生素A乳膏获得FDA批准，用于痤疮的局部治疗, objectType=article, longId=180539, objectId=0783180539fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0783180539fc, replyNumber=0, likeNumber=71, createdTime=2020-05-08, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0783180539fc, moduleTitle=Galderma的新型类维生素A乳膏获得FDA批准，用于痤疮的局部治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0783180539fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839805, encodeId=31ee18398058a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤, objectType=article, longId=193383, objectId=4d63193383b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d63193383b1, replyNumber=0, likeNumber=72, createdTime=2020-05-15, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d63193383b1, moduleTitle=FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d63193383b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839747, encodeId=0d6c1839e4774, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, objectType=article, longId=183486, objectId=889518348636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=889518348636, replyNumber=0, likeNumber=68, createdTime=2020-05-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=889518348636, moduleTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=889518348636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839766, encodeId=c4ac1839e66c4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查, objectType=article, longId=188100, objectId=0b4e188100f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4e188100f8, replyNumber=0, likeNumber=84, createdTime=2020-09-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4e188100f8, moduleTitle=FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b4e188100f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839788, encodeId=ba191839e884a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, objectType=article, longId=191241, objectId=eff619124151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eff619124151, replyNumber=0, likeNumber=57, createdTime=2021-02-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eff619124151, moduleTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eff619124151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839850, encodeId=12ff1839850a5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准非阿片类镇痛药Orphengesic Forte, objectType=article, longId=197686, objectId=df5219e68688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df5219e68688, replyNumber=0, likeNumber=68, createdTime=2020-08-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df5219e68688, moduleTitle=FDA批准非阿片类镇痛药Orphengesic Forte, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df5219e68688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839861, encodeId=4efe1839861b9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准口服性脊髓性肌萎缩症（SMA）药物Evrysdi, objectType=article, longId=199056, objectId=7cd91990560b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cd91990560b, replyNumber=0, likeNumber=61, createdTime=2020-11-29, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cd91990560b, moduleTitle=FDA批准口服性脊髓性肌萎缩症（SMA）药物Evrysdi, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cd91990560b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839819, encodeId=c2be18398192e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=92, createdTime=2021-04-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839729, encodeId=89671839e29d1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了**种增加红细胞生成性原卟啉病患者无痛光照的黑色素生成药Scenesse, objectType=article, longId=181141, objectId=04d9181141bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04d9181141bf, replyNumber=0, likeNumber=74, createdTime=2019-11-05, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04d9181141bf, moduleTitle=FDA批准了**种增加红细胞生成性原卟啉病患者无痛光照的黑色素生成药Scenesse, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04d9181141bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839720, encodeId=b47d1839e207a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准天花和猴痘疫苗Jynneos上市, objectType=article, longId=180049, objectId=ce9518004971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce9518004971, replyNumber=0, likeNumber=71, createdTime=2020-03-07, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce9518004971, moduleTitle=FDA批准天花和猴痘疫苗Jynneos上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce9518004971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839741, encodeId=a4391839e412b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准针对TMB的癌症全外显子组临床基因检测产品, objectType=article, longId=183019, objectId=24cc183019c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24cc183019c5, replyNumber=0, likeNumber=66, createdTime=2020-03-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24cc183019c5, moduleTitle=FDA批准针对TMB的癌症全外显子组临床基因检测产品, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24cc183019c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤

2020-06-30

bugit (审核中...)

前往app查看评论内容

#FDA批准#

**胆管癌靶向治疗药物获得美国FDA批准！

2021-03-15

bugit (审核中...)

前往app查看评论内容

#FDA批准#

慢性皮肤病及呼吸道疾病患者的福音：FDA批准Dupixent（dupilumab）300mg预填充笔

2021-01-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准默沙东的抗生素组合Recarbrio，治疗细菌性肺炎

2021-02-25

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准XARACOLL（盐酸布比卡因）植入物，用于缓解术后疼痛

2021-01-01

bugit (审核中...)

前往app查看评论内容

#FDA批准#

糖尿病性胃轻瘫：FDA批准甲氧氯普胺鼻喷剂Gimoti上市

2021-04-23

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌

2020-07-16

bugit (审核中...)

前往app查看评论内容

#FDA批准#

罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤

2021-03-06

bugit (审核中...)

前往app查看评论内容

#FDA批准#

20年首次突破！FDA批准卡格列净治疗“糖尿病肾病”适应症！

2020-07-15

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Galderma的新型类维生素A乳膏获得FDA批准，用于痤疮的局部治疗

2020-05-08

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤

2020-05-15

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症

2020-05-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查

2020-09-23

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗

2021-02-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准非阿片类镇痛药Orphengesic Forte

2020-08-04

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准口服性脊髓性肌萎缩症（SMA）药物Evrysdi

2020-11-29

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2021-04-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了**种增加红细胞生成性原卟啉病患者无痛光照的黑色素生成药Scenesse

2019-11-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准天花和猴痘疫苗Jynneos上市

2020-03-07

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准针对TMB的癌症全外显子组临床基因检测产品

2020-03-23

科室
- - 订阅+
  - 更多科室
工具
服务